We will investigate whether ultrahypofractionation using stereotactic ablative radiotherapy (SABR) or brachytherapy is as well-tolerated as moderately hypofractionated external beam radiotherapy (EBRT) for treating the prostate in patients with oligometastatic prostate cancer. Secondary aims include assessment of progression-free survival (PFS) and overall survival (OS) as well as cost-effectiveness. We hypothesize that ultrahypofractionation will maintain favorable toxicity profiles and quality of life while achieving comparable or better efficacy, thereby providing a convenient and cost-effective alternative to moderately hypofractionated EBRT.
Signed study specific informed consent
European Cooperative Oncology Group performance status 0 to 2
Histologically confirmed adenocarcinoma of the prostate
Any Tumor stage, any T, any N, M1
High metastatic burden defined as 5 or more bone metastases or visceral metastases
Contraindications to EBRT such as active inflammatory bowel disease or previous pelvic radiation
For Brachytherapy Arms =: Any prior Transurethral resection of prostate
British Columbia Cancer Agency
Lead sponsor